Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is a biotechnology company focused on eye-care products in the US market, with a promising future of revenue growth through future product launches and strategic changes to address current challenges. Despite a decrease in Q1 revenue due to high deductible plans, the company remains confident in their 2026 revenue guidance and has implemented a new sales force to target even more markets for their underutilized products. With successful identification and utilization of underutilized drugs and the launch of new products like MELT, Harrow's stock has a positive outlook for potential growth in the coming years.

Bears say

Harrow is currently facing challenges with the performance of its product, Vevye, due to seasonality in the industry and a decrease in demand for high deductible health plans. This has led to a decrease in revenue and could impact the success of new product acquisitions.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.